New biologic KD6005 tested in first human trial for rheumatoid arthritis
Disease control
Completed
This early-stage trial tested a new biologic drug called KD6005 in 73 people: first in healthy volunteers, then in patients with rheumatoid arthritis. The main goal was to check safety and how the body processes the drug. It is too soon to know if KD6005 works, but this study is …
Phase: PHASE1 • Sponsor: Shanghai Kanda Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC